Reports
Reports
Sale
The global fiducial markers market size was valued at USD 136 million in 2023, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to achieve a value of USD 237.8 million by 2032.
Fiducial markers are small metallic or polymer objects, often resembling the size of a grain of rice, strategically placed within or near a target area, such as a tumour, for various applications. In radiation therapies, these markers are used as essential guides, aiding healthcare providers in precisely aligning radiation beams to focus treatment on the targeted tumour while avoiding damage to surrounding healthy tissues. The placement of fiducial markers is minimally invasive, involving a fine needle, and is generally painless and inconspicuous to the patient. Beyond medical applications, fiducial markers find use in high-resolution optical microscopy, where they actively stabilize the field of view. Additionally, they serve as reference points in scientific experiments, including physics investigations like measuring the time of a pendulum and ensuring accurate and consistent measurements.
The market for fiducial markers has been witnessing significant growth during the historical period. This could be attributed to a variety of factors, including the growing incidence of cancer, which has led to an increased demand for precision radiotherapy procedures. With rising awareness about the benefits of radiotherapy in cancer treatment, both patients and healthcare providers are increasingly opting for these therapies.
Additionally, the surge in public and private funding for cancer research has accelerated the development and adoption of advanced radiotherapy techniques, including the use of fiducial markers. These markers play a crucial role in enhancing the accuracy of radiotherapy procedures, ensuring that cancer cells are effectively targeted. The increasing number of clinical studies to analyze multiple aspects and variations of treatments including their cost effectiveness and economic features are also driving the global fiducial markers market growth.
Moreover, a study published on PMC has shed light on the cost-effectiveness of MRI-only radiotherapy, emphasizing the importance of well-established workflows and margin reduction. As the usage of radiotherapy continues to rise as a vital component of cancer treatment, the fiducial markers market is expected to witness further growth and innovation in the coming years.
Market by Product Type
Market Breakup by Modality
Market Breakup by Cancer Type
Market Breakup by End User
Market Breakup by Region
The growth of the market is primarily driven by the increased awareness of the importance of early cancer detection and the effectiveness of subsequent treatments. With cancer incidence rates on the rise, there is a growing need for advanced radiotherapy procedures, leading to an increased demand for fiducial markers. Furthermore, the adoption of radiotherapy treatments is steadily increasing, driven by the preference for non-invasive and precise cancer therapies.
Fiducial markers are finding significant utilization in the treatment of prostate cancer, which is contributing to their increased adoption, further propelling the fiducial markers market growth. Additionally, the rising use of advanced radiotherapy techniques such as Stereotactic Body Radiation Therapy (SBRT) and Image Guided Radiation Therapy (IGRT), is also contributing to the demand for fiducial markers.
North America is currently dominating the global fiducial markers market share and is expected to keep leading the regional market in the coming years as well. This can be attributed to factors such as the high prevalence of cancer in the region, the presence of numerous key market players, increased research and development activities coupled with huge investments, heightened patient awareness, favourable reimbursement policies, and ongoing technological advancements in advanced radiotherapy procedures and imaging modalities. The combination of these factors is expected to fuel the growth of the market during the forecast period.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Modality |
|
Breakup by Cancer Type |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Fiducial Markers Market Overview
3.1 Global Fiducial Markers Market Historical Value (2017-2023)
3.2 Global Fiducial Markers Market Forecast Value (2024-2032)
4 Global Fiducial Markers Market Landscape
4.1 Fiducial Markers: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Fiducial Markers: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Global Fiducial Markers Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Fiducial Markers Market Segmentation
6.1 Global Fiducial Markers Market by Product Type
6.1.1 Market Overview
6.1.2 Metal Based Markers
6.1.3 Polymer Based Markers
6.1.4 Other Fiducial Markers
6.2 Global Fiducial Markers Market by Modality
6.2.1 Market Overview
6.2.2 CT/CBCT
6.2.3 MRI
6.2.4 Radiotherapy
6.2.5 Ultrasound
6.3 Global Fiducial Markers Market by Cancer Type
6.3.1 Market Overview
6.3.2 Lung Cancer
6.3.3 Breast Cancer
6.3.4 Gastric Cancer
6.3.5 Prostate Cancer
6.3.6 Other Cancers
6.4 Global Fiducial Markers Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Outpatient Facilities
6.4.3 Cancer Research Centres
6.4.4 Independent Radiotherapy Centres
6.5 Global Fiducial Markers Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Fiducial Markers Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Fiducial Markers Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Fiducial Markers Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Fiducial Markers Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Fiducial Markers Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 IZI Medical Products
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Medtech
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Best Medical International
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Nanovi A/S.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Naslund Medical AB
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Medtronic
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 CIVCO Radiotherapy
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Medtronic Plc
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Boston Scientific Corporation
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 136 million in 2023, driven by increasing research activities.
The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032, likely to reach a market value of USD 237.8 million by 2032.
The increasing incidence of cancer and increasing demand for fiducial markers are among the major factors driving the market growth.
The heightened patient awareness and public and private funding for cancer research are among the major trends influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Various products in the market include metal-based markers and polymer-based markers, among other fiducial markers.
Modalities include CT/CBCT, MRI, radiotherapy, and ultrasound.
Detectable cancers include lung cancer, breast cancer, gastric cancer, and prostate cancer, among other cancers.
End users in the market are hospitals and outpatient facilities, cancer research centres, and independent radiotherapy centres.
Key players involved in the market are IZI Medical Products, Medtech, Best Medical International, Nanovi A/S., Naslund Medical AB, Medtronic, CIVCO Radiotherapy, Medtronic Plc, and Boston Scientific Corporation.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.